|Astex focused on creating value for investors in 2012|
|By Staff and Wire Reports|
|Friday, 27 April 2012 07:23|
In February, Astex shares got hammered after regulators turned a skeptical eye on a leukemia-related drug the company licensed to Eisai. More recently, the pharmaceutical company presented data on their novel, first-in-class, direct acting antiviral agent (DAA) against Hepatitis C Virus (HCV) at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL): The International Liver Congress™, April 18 to 22, 2012 in Barcelona, Spain. Although technical, the posters below showcase the strength of Astex’s Pyramid™ technology to deliver promising new pipeline assets and highlight Astex’s move into a new therapeutic area.
Poster 19057 [here in pdf form] explains the selection process of the preclinical candidates using Astex’s industry-leading Pyramid fragment screening technology. The results are the identity of a new druggable binding site (clinically proven) on the serine protease of the Hep C virus, NS3, and the discovery of the two novel compounds.
Poster 19064 [here in pdf form] follows on from the previous poster, explaining the development process of the two compounds into preclinical candidates and their optimisation with respect to human pharmacokinetics and improved potency. Key features of the design of these two compounds is the potential for once daily oral dosing and for their use in polytherapy regimes required for effective HCV treatment.
Given how hot stocks in the Hepatitis C Virus space have been on Wall Street, we reached out and asked CEO Manuso to walk us through some key questions about his firm and their platform:
BioMedReports: Astex are focused mainly on oncology and have a successful myelodysplastic syndrome (MDS) product in Dacogen™(decitabine). What prompted this work into virology and specifically HCV?
James S.J. Manuso, PhD: The Pyramid™ discovery platform is agnostic to indications and has been successfully used against targets from many therapeutic areas in partnerships with big pharma. HCV was targeted given the need for new anti-virals with novel mechanisms of action.
BioMedReports: Could you describe the benefits of your fragment-based Pyramid™ system and why it is suited to the development of the compound?
James S.J. Manuso, PhD: Our discovery methodology allows us to find drugs against different target binding sites, such as allosteric pockets, compared with traditional high-throughput screening.
BioMedReports: What is it about AT26893 that distinguishes it from other direct acting antiviral agents (DAA) currently on the market or in development?
James S.J. Manuso, PhD: Unlike other DAAs AT26893 targets a novel binding site between the protease and helicase domains, and represents the first allosteric, non-competitive inhibitor of the NS3 protein which may confer a complementary clinical activity.
BioMedReports: AT26893 is in pre-clinical development now – when do you anticipate starting phase I trials?
James S.J. Manuso, PhD: We have not given guidance on that timeline yet. The current status is preclinical.
BioMedReports: Astex has successfully partnered several of its pipeline assets with a number of companies, including GSK, Novartis, AstraZeneca and Janssen. Are you looking for a partner for this asset?
James S.J. Manuso, PhD: As data develops, we are discussing the possibility of partnering with appropriate companies.
BioMedReports: What are Astex's most important catalysts/milestones investors should be aware of this year?
James S.J. Manuso, PhD: Dacogen EMA review of an AML submission by JNJ and four phase II data read outs in the fourth quarter.
BioMedReports: What are the biggest challenges for the company?
James S.J. Manuso, PhD: Identifying the right biology that will result in addressing the unmet medical need we are targeting.
BioMedReports: What are the biggest opportunities?
James S.J. Manuso, PhD: Surprising investors with significant value creation in 2012.